The company's lead program, a bi-specific called Sutacimig, has already reported phase 2 data for Glanzmann Thrombasthenia, and will start a pivotal in 2026. Hemab also has a monovalent antibody (HMB-022) in the clinic for the world's most common bleeding disorder, Von Willebrand Disease, and will be announcing an additional candidate next year.